Late Line Therapy in Multiple Myeloma ➡️
Dr. Jason Chandler discussed the management of what he calls “penta-refractory” multiple myeloma (MM) patients and the available treatment options at the 2023 West Oncology Conference.
He shared that relapsed or refractory #MultipleMyeloma is an incurable diagnosis, but thankfully one with an increasing number of treatment options. Providers should be aware of and familiarize themselves with new treatments as they are becoming available for this population. Many patients have the potential for significantly longer life-spans who were previously shown to have only 21 months from time of first treatment.